Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk

Campbell D Joyner; Ron J G Peters; Rizwan Afzal; Susan Chrolavicius; Shamir R Mehta; Keith A A Fox; Christopher B Granger; Maria Grazia Franzosi; Marcus Flather; Andrzej Budaj; Jean-Pierre Bassand; Salim Yusuf

doi:10.1016/j.ahj.2008.10.028

Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk

Campbell D Joyner, Ron J G Peters, Rizwan Afzal, Susan Chrolavicius, Shamir R Mehta, Keith A A Fox, Christopher B Granger, Maria Grazia Franzosi, Marcus Flather, Andrzej Budaj, Jean-Pierre Bassand, Salim Yusuf

Research output: Contribution to journal › Article › peer-review

30 Citations (Scopus)

Abstract

The OASIS-5 (Organization to Assess Strategies in Ischemic Syndromes-5) trial demonstrated that fondaparinux was noninferior to enoxaparin while reducing the risk of bleeding by 50%. The objectives of our study were to assess the effects of fondaparinux compared to enoxaparin in patients stratified by their Global Registry of Acute Coronary Events (GRACE) score and to examine the ability of the GRACE score to predict bleeding in patients with acute coronary syndromes (ACS).

Original language	English
Pages (from-to)	502-8
Number of pages	7
Journal	American Heart Journal
Volume	157
Issue number	3
DOIs	https://doi.org/10.1016/j.ahj.2008.10.028
Publication status	Published - Mar 2009

Keywords

Acute Coronary Syndrome
Anticoagulants
Enoxaparin
Hemorrhage
Humans
Polysaccharides
Prognosis
Risk Assessment
Treatment Outcome

Access to Document

10.1016/j.ahj.2008.10.028

Cite this

Joyner, C. D., Peters, R. J. G., Afzal, R., Chrolavicius, S., Mehta, S. R., Fox, K. A. A., Granger, C. B., Franzosi, M. G., Flather, M., Budaj, A., Bassand, J-P., & Yusuf, S. (2009). Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk. American Heart Journal, 157(3), 502-8. https://doi.org/10.1016/j.ahj.2008.10.028

@article{910ae21f8dae41bd820c5bc74b99ce6c,

title = "Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk",

abstract = "The OASIS-5 (Organization to Assess Strategies in Ischemic Syndromes-5) trial demonstrated that fondaparinux was noninferior to enoxaparin while reducing the risk of bleeding by 50%. The objectives of our study were to assess the effects of fondaparinux compared to enoxaparin in patients stratified by their Global Registry of Acute Coronary Events (GRACE) score and to examine the ability of the GRACE score to predict bleeding in patients with acute coronary syndromes (ACS).",

keywords = "Acute Coronary Syndrome, Anticoagulants, Enoxaparin, Hemorrhage, Humans, Polysaccharides, Prognosis, Risk Assessment, Treatment Outcome",

author = "Joyner, {Campbell D} and Peters, {Ron J G} and Rizwan Afzal and Susan Chrolavicius and Mehta, {Shamir R} and Fox, {Keith A A} and Granger, {Christopher B} and Franzosi, {Maria Grazia} and Marcus Flather and Andrzej Budaj and Jean-Pierre Bassand and Salim Yusuf",

year = "2009",

month = mar,

doi = "10.1016/j.ahj.2008.10.028",

language = "English",

volume = "157",

pages = "502--8",

journal = "American Heart Journal",

issn = "0002-8703",

publisher = "Mosby Inc.",

number = "3",

}

Joyner, CD, Peters, RJG, Afzal, R, Chrolavicius, S, Mehta, SR, Fox, KAA, Granger, CB, Franzosi, MG, Flather, M, Budaj, A, Bassand, J-P & Yusuf, S 2009, 'Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk', American Heart Journal, vol. 157, no. 3, pp. 502-8. https://doi.org/10.1016/j.ahj.2008.10.028

TY - JOUR

T1 - Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation

T2 - outcomes and treatment effect across different levels of risk

AU - Joyner, Campbell D

AU - Peters, Ron J G

AU - Afzal, Rizwan

AU - Chrolavicius, Susan

AU - Mehta, Shamir R

AU - Fox, Keith A A

AU - Granger, Christopher B

AU - Franzosi, Maria Grazia

AU - Flather, Marcus

AU - Budaj, Andrzej

AU - Bassand, Jean-Pierre

AU - Yusuf, Salim

PY - 2009/3

Y1 - 2009/3

N2 - The OASIS-5 (Organization to Assess Strategies in Ischemic Syndromes-5) trial demonstrated that fondaparinux was noninferior to enoxaparin while reducing the risk of bleeding by 50%. The objectives of our study were to assess the effects of fondaparinux compared to enoxaparin in patients stratified by their Global Registry of Acute Coronary Events (GRACE) score and to examine the ability of the GRACE score to predict bleeding in patients with acute coronary syndromes (ACS).

AB - The OASIS-5 (Organization to Assess Strategies in Ischemic Syndromes-5) trial demonstrated that fondaparinux was noninferior to enoxaparin while reducing the risk of bleeding by 50%. The objectives of our study were to assess the effects of fondaparinux compared to enoxaparin in patients stratified by their Global Registry of Acute Coronary Events (GRACE) score and to examine the ability of the GRACE score to predict bleeding in patients with acute coronary syndromes (ACS).

KW - Acute Coronary Syndrome

KW - Anticoagulants

KW - Enoxaparin

KW - Hemorrhage

KW - Humans

KW - Polysaccharides

KW - Prognosis

KW - Risk Assessment

KW - Treatment Outcome

U2 - 10.1016/j.ahj.2008.10.028

DO - 10.1016/j.ahj.2008.10.028

M3 - Article

C2 - 19249421

VL - 157

SP - 502

EP - 508

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 3

ER -